New Peptide ETF From REX Looks Beyond GLP-1 Drugs
A new peptide ETF launched today, holding the drugmakers behind GLP-1 weight-loss treatments along with the companies that make and deliver them. Key Takeaways: REX’s new fund follows 36 peptide-linked companies, ranging from GLP-1 drugmakers to device and supplement makers. Eli Lilly, Novo Nordisk, and Ascendis Pharma each carry index weights near or above 10%. [...]
The post New Peptide ETF From REX Looks Beyond GLP-1 Drugs appeared first on ETF Trends .